These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 27678175)

  • 1. Application of Nanomedicine to the CNS Diseases.
    Carradori D; Gaudin A; Brambilla D; Andrieux K
    Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
    Baby N; Patnala R; Ling EA; Dheen ST
    Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology-based drug delivery for central nervous system disorders.
    Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
    Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases.
    Mansor NI; Nordin N; Mohamed F; Ling KH; Rosli R; Hassan Z
    Curr Drug Deliv; 2019; 16(8):698-711. PubMed ID: 31456519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.
    Patel MM; Patel BM
    CNS Drugs; 2017 Feb; 31(2):109-133. PubMed ID: 28101766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategy for effective brain drug delivery.
    Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
    Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
    Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches for encephalic drug delivery using nanomaterials: The current status.
    V A; Cutinho LI; Mourya P; Maxwell A; Thomas G; Rajput BS
    Brain Res Bull; 2020 Feb; 155():184-190. PubMed ID: 31790722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
    Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
    CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
    Zhou X; Smith QR; Liu X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.